Fly News Breaks for July 24, 2019
Jul 24, 2019 | 12:25 EDT
Boston Scientific's Q2 results were essentially in line with consensus estimates as "some concerning areas" from Q1 persisted, such as Neuromod, but were offset by faster growth areas like Medsurg and Structural Heart, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The second half of 2019 acceleration in the core business, implied by the unchanged guidance, is achievable, says the analyst. He reiterates an Overweight rating on Boston Scientific shares with a $50 price target.
News For BSX From the Last 2 Days
Sep 20, 2019 | 07:29 EDT
Cowen analyst Joshua Jennings said Boston Scientific is setting up for a batter second half to the year as the company has a steady flow of product launches scheduled for the second half and should also experience momentum in its core businesses over that interval. In addition, there is one more selling day in the second half versus one less in the first. Jennings reiterated his Outperform rating and $47 price target on Boston Scientific shares.